Wall Street brokerages expect CorMedix Inc (NASDAQ:CRMD) to post earnings per share (EPS) of ($0.23) for the current fiscal quarter, according to Zacks. Two analysts have made estimates for CorMedix’s earnings. CorMedix posted earnings per share of $0.10 during the same quarter last year, which would indicate a negative year-over-year growth rate of 330%. The company is scheduled to announce its next quarterly earnings results on Thursday, March 12th.
According to Zacks, analysts expect that CorMedix will report full-year earnings of ($0.70) per share for the current financial year. For the next financial year, analysts expect that the company will post earnings of ($1.04) per share. Zacks’ EPS calculations are a mean average based on a survey of analysts that follow CorMedix.
NASDAQ CRMD opened at $6.59 on Monday. The company’s 50 day moving average is $5.92 and its 200-day moving average is $7.29. CorMedix has a 12-month low of $4.86 and a 12-month high of $13.70.
CorMedix, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology.
Further Reading: Percentage Decliners
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.